Patent application number | Description | Published |
20100196386 | LIGANDS OF HVEM FOR TREATING HEMATOLOGIC MALIGNANCIES AND AUTOIMMUNE DISEASES - The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases. | 08-05-2010 |
20110177088 | Method for Treating and Diagnosing Hematologic Malignancies - The invention relates to methods for treating and diagnosing hematologic malignancies, Chronic lymphocytic leukemia and Small Lymphocytic Lymphoma in particular, using PD-1 ligands (PD-L1, PD-L2 or anti-PD-1 antibodies). | 07-21-2011 |
20120039906 | PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof - The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof. | 02-16-2012 |
20120064096 | BTLA Antibodies and Uses Thereof - The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof. | 03-15-2012 |
20140086923 | Antibodies Directed Against ICOS and Uses Thereof - The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg. | 03-27-2014 |
20140178394 | NOVEL ANTIGEN PEPTIDE AND USES THEREOF - The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer. | 06-26-2014 |
20140322235 | ANTI-CD277 ANTIBODIES AND USES THEREOF - The present invention relates to anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vy9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The invention also relates to the use of said antibodies in therapy. | 10-30-2014 |
20140335093 | PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof - The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof. | 11-13-2014 |